Does Dr. JENNIFER AGREN have financial conflicts of interest?

Dr. JENNIFER AGREN (MD) has received a total of $692 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $692 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. JENNIFER AGREN?

According to CMS Open Payments data, Dr. JENNIFER AGREN received funding from UNITED THERAPEUTICS CORPORATION ($483) and BOEHRINGER INGELHEIM PHARMACEUTICALS ($210).

Does Dr. JENNIFER AGREN receive research grants or speaking fees?

Dr. JENNIFER AGREN has received $692 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. JENNIFER AGREN

MDReal-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: SOUTH PORTLAND, ME 04106

NPI Number: 1649430893

LIFETIME INDUSTRY VALUE

$692

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. AGREN is a verified Internal Medicine, Pulmonary Disease practitioner based in SOUTH PORTLAND, ME.

Between 2021 and 2025, Dr. AGREN had an overall industry promotional and research financial footprint of $692 as recorded in the federal CMS Open Payments database.

$692 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AGREN's primary funding source is UNITED THERAPEUTICS CORPORATION, which accounts for $483 (representing 69.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

UNITED THERAPEUTICS CORPORATION

Rank 1

$483

69.7%

BOEHRINGER INGELHEIM PHARMACEUTICALS

Rank 2

$210

30.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.